Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 7/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15760260 | 0.82 | ACKR3 (0.43) | ACKR3PTPN11AKT1KCNH2 | |
| Hydrochloric Acid SCHEMBL15754846 | 0.81 | ACKR3 (0.42) | ACKR3PTPN11AKT1KCNH2 | |
| SCHEMBL15760262 | 0.81 | ACKR3 (0.39) | ACKR3RIPK1 | |
| SCHEMBL17697115 | 0.70 | CYP2D6 (0.48) | AKT1 | |
| SCHEMBL15760561 | 0.69 | ACKR3 (0.36) | ACKR3 | |
| SCHEMBL20021215 | 0.68 | HTR2C (0.45) | ACKR3NUDT1 | |
| SCHEMBL5496661 | 0.64 | HTR2C (0.65) | — | |
| SCHEMBL7324694 | 0.64 | PIK3R1 (0.55) | ACKR3 | |
| SCHEMBL15760276 | 0.63 | ACKR3 (0.43) | ACKR3 | |
| SCHEMBL15754793 | 0.63 | ACKR3 (0.46) | ACKR3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2925745-B1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783544-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783544-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160145259-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145259-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9169261-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169261-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287292-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-11059825-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-20160145259-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885PTPN11 771/4885NUDT1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.